BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harsányi A, Csanádi M, Márky K, Vincziczki ÁZ, Kaló Z, Inotai A. Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. Expert Rev Pharmacoecon Outcomes Res 2020;20:653-9. [PMID: 31510811 DOI: 10.1080/14737167.2019.1667232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Tesar T, Golias P, Masarykova L, Kawalec P, Inotai A. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia. Front Pharmacol 2021;12:795002. [PMID: 34966285 DOI: 10.3389/fphar.2021.795002] [Reference Citation Analysis]
2 Rahalkar H, Sheppard A, Salek S. Biosimilar development and review process in the BRICS-TM countries: proposal for a standardized model to improve regulatory performance. Expert Rev Clin Pharmacol 2022. [PMID: 35078378 DOI: 10.1080/17512433.2022.2034498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, Kalemeera F, Hoxha I, Nachtnebel A, Sauermann R, Hinteregger M, Marković-Peković V, Tubic B, Petrova G, Tachkov K, Slabý J, Nejezchlebova R, Krulichová IS, Laius O, Selke G, Langner I, Harsanyi A, Inotai A, Jakupi A, Henkuzens S, Garuolienė K, Gulbinovič J, Bonanno PV, Rutkowski J, Ingeberg S, Melien Ø, Mardare I, Fürst J, MacBride-Stewart S, Holmes C, Pontes C, Zara C, Pedrola MT, Hoffmann M, Kourafalos V, Pisana A, Banzi R, Campbell S, Wettermark B. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. Biomed Res Int 2021;2021:9996193. [PMID: 34676266 DOI: 10.1155/2021/9996193] [Reference Citation Analysis]
4 Inotai A, Kaló Z. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways. Expert Rev Pharmacoecon Outcomes Res 2019;19:627-32. [PMID: 31810392 DOI: 10.1080/14737167.2019.1702524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]